Paige, a leader in artificial intelligence (AI) technology, introduces Paige Alba™, a clinical-grade AI co-pilot designed to transform personalized medicine and precision oncology.
Alba leverages Paige’s advanced AI models to provide real-time patient insights. It combines computational pathology and conversational language capabilities, offering healthcare professionals a comprehensive and interactive experience.
One key feature of Alba is its ability to aggregate patient data from various sources, such as electronic health records, laboratory systems, and imaging databases. This eliminates manual data entry, saves pathologists valuable time, and reduces administrative burdens.
In addition to its diagnostic capabilities, Alba assists in workflow management. It can order stains, complete reports, and process images through voice commands, streamlining routine tasks.
Alba also integrates clinical, pathological, and biomarker data, providing a consolidated view of patient information. This helps physicians make precise diagnostic recommendations and generate pathology reports efficiently.
Razik Yousfi, CEO of Paige, indicated that Alba empowers clinicians with a truly intelligent and interactive co-pilot, ensuring they have the most relevant and timely information to guide their decisions.
Alba is currently available for research purposes only and not for diagnostic use.
Paige’s mission is to advance AI technology in healthcare, enabling clinicians to deliver personalized and effective patient care. Alba represents a significant step towards this goal, revolutionizing precision oncology and empowering healthcare professionals with the tools they need to improve patient outcomes.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
